Sandoz Group AG

4 days ago · prnewswire.com

mAbxience and Sandoz have entered into a collaboration agreement combining mAbxience's development and manufacturing expertise with Sandoz's global commercial capabilities for a proposed emicizumab biosimilar candidate. Emicizumab biosimilar expands mAbxience's pipeline into haemophilia A and strengthens its presence in rare diseases.

4 days ago · wsj.com

The approval for its generic version of diabetes drug Ozempic advances its efforts to build a portfolio of GLP-1 medicines.

13 days ago · seekingalpha.com

Sandoz Group AG (SDZNY) Analyst/Investor Day Transcript

14 days ago · zacks.com

Investors interested in Medical - Drugs stocks are likely familiar with Grifols (GRFS) and Sandoz Group AG Sponsored ADR (SDZNY). But which of these two companies is the best option for those looking for undervalued stocks?

15 days ago · reuters.com

Sandoz aims to more ​than double net sales from ‌2025 to 2035, the Swiss drug maker said on Tuesday at its capital markets day, ​where it outlined its new ​Bio100 biosimilars strategy, pivoting its focus from ⁠generics to biosimilars.

26 days ago · zacks.com

The Medical - Generic Drugs industry gains from new launches, biosimilar momentum and portfolio shifts, despite pricing pressure and supply challenges.

1 month ago · prnewswire.com

Collaboration may cover up to 10 proposed monoclonal antibody (mAb) and/or antibody-drug conjugate (ADC) biosimilar assets, with the majority of programs at early development stages Based on the initial arrangements, the total invoiced amount expected to be achieved by Henlius in 2026 is up to US$100.5 million The collaboration further expands the parties' 2025 oncology biosimilars partnership SHANGHAI, Aug. 17, 2026 /PRNewswire/ -- On August 17, 2026, Shanghai Henlius Biotech, Inc. (2696.HK) announced that it has entered into a strategic collaboration with Sandoz (SIX: SDZ; OTCQX: SDZNY), a global leader in generics and biosimilars, covering up to 10 proposed monoclonal antibody (mAb) and/or antibody-drug conjugate (ADC) biosimilar products or components developed by Henlius. The parties have also signed collaboration terms for an initial three agreed products and an option for one additional asset.

1 month ago · reuters.com

Swiss generic drugmaker Sandoz will pay up to $77 million ​upfront to Shanghai Henlius Biotech for rights to ‌three biosimilar drugs to treat cholesterol, lupus and colorectal cancer, the Chinese drugmaker said on Monday.

2 months ago · seekingalpha.com

Sandoz Group AG (SDZNY) Q2 2026 Earnings Call Transcript

2 months ago · wsj.com

Sandoz Group reported higher sales for the second quarter, driven by a strong performance in its biosimilar segment and a return to growth in generics.